Imaging Test Using CD70 Targeting for Kidney Cancer and Lymphoma
Tests a CD70-targeted PET scan to help detect kidney cancer and lymphoma in adults.
Plain-language title generated from the registry record
Registry title: CD70-targeted immunoPET Imaging of Malignant Cancers
Key facts
- Where
- Shanghai, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06852638, who can take part
Where in China
- Renji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- RenJi Hospital
- Trial code
- NCT06852638
- Record updated
- 12 May 2026
- Original description
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.Read full original descriptionShow less
CD70-targeted PET/ CT in the Diagnosis of Malignant Cancers
This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.
Inclusion: Aged 18-80 year-old and of either sex；; Histologically confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging; Capable of giving signed informed consent, including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.
Exclusion: Severe hepatic and renal insufficiency; Allergic to single-domain antibody radiopharmaceuticals; Pregnancy；.